Status:
UNKNOWN
Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension
Lead Sponsor:
Krasnoyarsk Regional Hospital
Conditions:
Atrial Fibrillation
Hypertension, Pulmonary
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Some patients with a long history of AF develops PH "reactive" type with an increase in pulmonary vascular resistance due to vasoconstriction or structural changes of the vascular wall. RFA PVI + RFA ...
Eligibility Criteria
Inclusion
- Patients with symptomatic, drug - refractory AF ( inefficiency 1C or III Class antiarrhythmic drugs), history of AF 6 months or more without the restoration of sinus rhythm.
- MPAP ≥25 mmHg
- PCWP≥15 mmHg
- Pulmonary vascular resistance (PVR). The PVR =(mPAP-PCWP)/ carbon monoxide\] \> 2.5 woods unit
Exclusion
- Left ventricular ejection fraction \<35%
- Diameter LA\> 60 mm on transthoracic echocardiography in the "M" -Mode or volume of LA more than 140 ml
- Significant regurgitation at the mitral valve
- Uncorrected congenital heart disease
- RFA PVI, RFA GP, PADN in history
- Foregoing heart surgery
- Life expectancy less than 12 months
- WHO group I, III, IV, V pulmonary artery hypertension
- Tricuspid valve stenosis, pulmonary supravalve stenosis.
- Cancer
- Pregnancy
- Thromboembolism LA history
- Hyperthyroidism.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2016
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02298244
Start Date
January 1 2015
End Date
November 1 2016
Last Update
November 21 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.